VRTX Vertex Pharmaceuticals Incorporated

185.76
+2.7  (+1%)
Previous Close 183.06
Open 184.33
Price To Book 10.7
Market Cap 47472460582
Shares 255,558,035
Volume 960,423
Short Ratio
Av. Daily Volume 1,542,127

NewsSee all news

  1. The Zacks Analyst Blog Highlights: Nike, 3M, Vertex, PepsiCo and Verisk
  2. The Top 5 Biotech Stocks Are Facing Growth Challenges — Are Any Immune?
  3. Vertex Appoints Lloyd Carney to its Board of Directors
  4. Top Stock Reports for Nike, 3M & Vertex
  5. The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

SEC filingsSee all SEC filings

  1. 8-K - Current report 19626431
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 19598115
  4. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 19597984
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595274

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 positive data released November 27, 2018. 14% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min)
PDUFA date under priority review February 28, 2017. Approval announced February 12, 2018.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
NDA filing due 1Q 2018.
ORKAMBI
Two Copies of the F508del Mutation - children ages 2 to 5
Phase 3 data released October 25, 2017 - primary endpoint not met.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation
Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points.
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data released December 18, 2018. Primary endpoint met.
VX-150
Neuropathic pain
Phase 2b data due 1H 2019.
VX-150
Acute pain following bunionectomy surgery
Phase 3 data released February 14, 2019 - primary endpoint met.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have two copies of the F508del mutation
Phase 3 positive data released November 27, 2018. 10% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Phase 3 data released February 14, 2019 - primary endpoint met.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation
Phase 1/2 trial initiated 4Q 2018.
CTX001
Sickle cell disease
Phase 1/2 trial enrolling.
CTX001
Beta-thalassemia
FDA Approval announced August 7, 2018.
Ivacaftor
Cystic fibrosis (CF) ages 2 to 5.
Approval announced August 15, 2018.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 1-2.
sNDA filing due late 2018.
Ivacaftor
Cystic Fibrosis (6-12 mths)
sNDA filing due late 2018.
Tezacaftor and ivacaftor
Cystic Fibrosis (Age 6-11)
Phase 2 monotherapy trial to commence 2H 2019.
VX-561
Cystic fibrosis who have a gating mutation

Latest News

  1. The Zacks Analyst Blog Highlights: Nike, 3M, Vertex, PepsiCo and Verisk
  2. The Top 5 Biotech Stocks Are Facing Growth Challenges — Are Any Immune?
  3. Vertex Appoints Lloyd Carney to its Board of Directors
  4. Top Stock Reports for Nike, 3M & Vertex
  5. The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
  6. Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
  7. Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
  8. 3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?
  9. Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission
  10. Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $20.1 million of Shares
  11. Have Insiders Been Selling Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares?
  12. Groupon (GRPN) to Report Q4 Earnings: What's in the Cards?
  13. This Is the Best Biotech Stock on the Market
  14. Check Out These 7 Fast-Growing Stocks to Buy Today
  15. See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
  16. Factors Likely to Influence Cisco's (CSCO) Earnings in Q2
  17. Factors Expected to Influence Akamai's (AKAM) Q4 Earnings
  18. Vertex Pharmaceuticals: New Drug, Same Great Growth Story
  19. The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

SEC Filings

  1. 8-K - Current report 19626431
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 19598115
  4. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 19597984
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595274
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19583393
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19572653
  8. 8-K - Current report 19568072
  9. 8-K - Current report 19537643
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership